ORION-10 A Placebo-Controlled, Double-Blind, Randomized Trial to
Evaluate the Effect of 300 mg of Inclisiran Sodium Given as
Subcutaneous Injections in Subjects With Atherosclerotic
Cardiovascular Disease (ASCVD) and Elevated Low-Density
Lipoprotein Cholesterol (LDL-C)
Please contact us for more information or to learn if you are eligible to participate.
